AstraZeneca (AZN) Tops Q3 EPS by 90c, Beats on Revenue

AstraZeneca (NASDAQ: AZN) reported Q3 EPS of $1.67, $0.90 better than the analyst estimate of $0.77. Revenue for the quarter came in at $10.98 billion versus the consensus estimate of $10.78 billion.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.

You May Also Be Interested In

• Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NS
• Pembina joins proposed 1M bbl/day Alberta-to-coast pipeline plan
• Goldman's Garrett sees investors dialing back tech exposure into H2